Hi,
Were the RNA-seq samples all collected prior to patient treatment or are some from patients on treatment?
Also should the predictions of PFS and OS be in days or months?
Thanks!
Created by rossinerbe Hi @Eimanahmed ,
Thanks for participating in this Challenge. The validation dataset is limited to those samples that have RNA-seq data but may be missing TMB. So all validation samples should have gene expression data. We do, however, recommend that models be designed to be robust to missing data in general.
Hope that helps,
Mike Hi @Michael.Mason
I would like to ask will the model be run in patients that missing gene expression data as well?
Thanks, Hi @rossinerbe ,
The data RNA-seq sampling was done prior to patient treatment.
The predictions should be in a format that allows for ranking with higher values indicating a higher likelihood to respond to Nivolumab. They could be a probability of response, integers etc.
Hope this helps,
Mike